Possible Biomarkers for Progression Independent of Relapse Activity Identified in RMS
Identification of candidate biomarkers associated with MS progression may enable earlier detection and individualized monitoring of Progression Independent of Relapse Activity (PIRA). According to Andrea Landwehr, who presented the results at the ECTRIMS 2025 Congress, these findings pave the way for novel therapeutic strategies that could significantly improve long-term outcomes and quality of life for people living with MS.
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen